abstract |
The present invention provides a method of treating certain neurological and psychiatric disorders in mammals, including humans, comprising administering a selective PDE10 inhibitor. The invention particularly relates to the treatment of mood, movement and anxiety disorders; psychosis; drugs, eg alcohol addiction; disorders with cognitive deficits as symptoms; and neurodegenerative disorders and symptoms. The present invention further provides the use of papaverine as a selective PDE10 inhibitor. The present invention also provides an assay for identifying compounds with activity as selective PDE10 inhibitors. |